Micro Cap
Drug Manufacturers - General
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
26
Theriva Biologics
TOVX
$9.78M
| $9.78M | $0.2130 | 4.44% |
|
|
APUS
27
Apimeds Pharmaceuticals US
APUS
$9.49M
| $9.49M | $6.29 | 11.3% |
|
|
AIM
28
AIM ImmunoTech
AIM
$6.93M
| $6.93M | $0.2500 | 0.4% |
|
|
CANF
29
Can-Fite BioPharma American Depositary Shares
CANF
$6.75M
| $6.75M | $3.15 | 1.25% |
|
|
KAPA
30
Kairos Pharma
KAPA
$6.63M
| $6.63M | $0.3098 | 8.7% |
|
31
Oragenics
OGEN
$2.26M
| $2.26M | $0.5010 | 1.96% |
|
32
BiomX
PHGE
$2.13M
| $2.13M | $0.1974 | 4.44% |
|
33
Matinas BioPharma
MTNB
$2.13M
| $2.13M | $0.3320 | 37.5% |
|
34
Calidi Biotherapeutics
CLDI
$2.11M
| $2.11M | $0.1095 | 9.5% |
|
35
Azitra
AZTR
$2.07M
| $2.07M | $0.1276 | 1.03% |
|
|
IMRA
36
Bitwise MARA Option Income Strategy ETF
IMRA
$1.89M
| $1.89M | $14.52 | 0% |
|
|
PTNT
37
Corgi IP Licensing & Royalties ETF
PTNT
$1.09M
| $1.09M | $24.23 | 1.38% |
|
|
ONTX
38
Corgi ONTO 2x Daily ETF
ONTX
$919K
| $919K | $15.31 | 8.05% |
|
Micro Cap Drug Manufacturers - General Stocks at a Glance
Large drug manufacturers sell diversified portfolios of branded medicines backed by deep development pipelines. Patent lives set the clock: blockbuster franchises fund the R&D and acquisitions needed to outrun expirations, supporting durable margins and dividends.
There are 38 micro cap Drug Manufacturers - General stocks — companies in the Drug Manufacturers - General industry with a market cap under $250M — worth a combined $1.37B.
The largest by market cap are Protalix BioTherapeutics (PLX) at $193M, Armata Pharmaceuticals (ARMP) at $189M and Innovator US Equity Ultra Buffer ETF November (UNOV) at $107M.
Among institutional investors, Protalix BioTherapeutics (PLX) drew the most net new fund positions in Q1 2026: 27 funds opened new positions, taking total fund holders up 16 (19%) quarter-over-quarter.
- Combined market cap: $1.37B across 38 stocks.
- Micro Cap: market cap under $250M.
- Largest constituent: Protalix BioTherapeutics (PLX), $193M market cap.
- Most net new fund positions in Q1 2026: Protalix BioTherapeutics (PLX), +16 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q1 2026.